MEI Pharma announced the dosing of the first patient in a Phase 1b study evaluating ME-344 in combination with bevacizumab in patients with previously treated metastatic colorectal cancer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MEIP:
- Infinity Pharmaceuticals terminates merger agreement with MEI Pharma
- MEI fails to obtain votes to approve merger with Infinity Pharmaceuticals
- Anson, Cable Car respond to MEI Pharma’s attempt to prohibit director removal
- MEI Pharma responds to consent solicitation launched by Anson
- Anson, Cable Car file materials to remove entire MEI Pharma board